^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CCR8 inhibitor

    Related drugs:
    3d
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=400, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    20d
    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Gilead Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    29d
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=450, Recruiting, Genentech, Inc. | Trial completion date: Feb 2027 --> Jul 2028 | Trial primary completion date: Feb 2027 --> Jul 2028
    Trial completion date • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab)
    30d
    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=170, Not yet recruiting, Gilead Sciences
    New P2 trial
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • denikitug (GS-1811)
    1m
    QLP2117-201: A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients (clinicaltrials.gov)
    P1/2, N=149, Recruiting, Qilu Pharmaceutical Co., Ltd. | N=90 --> 149
    Enrollment change
    1m
    IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Nanjing Immunophage Biotech Co., Ltd
    New P1/2 trial
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Loqtorzi (toripalimab-tpzi) • IPG7236
    1m
    CHS-114-102: A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=154, Recruiting, Coherus Oncology, Inc. | Trial completion date: May 2027 --> Jan 2028 | Trial primary completion date: May 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • BRAF V600 • RAS wild-type
    |
    cisplatin • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    2ms
    A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=129, Active, not recruiting, Bayer | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab)
    2ms
    SRF114-101: Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=87, Recruiting, Coherus Oncology, Inc. | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> Sep 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    2ms
    aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=282, Recruiting, Shionogi | Trial completion date: Apr 2027 --> May 2028 | Trial primary completion date: Apr 2027 --> May 2028
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • S-531011
    2ms
    BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=99, Terminated, BeiGene | N=263 --> 99 | Trial completion date: Mar 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Jan 2026; This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    2ms
    Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C (clinicaltrials.gov)
    P1/2, N=72, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • albumin-bound paclitaxel • Anniko (penpulimab-kcqx) • cafelkibart (LM-108)